BLOG

endpoints

Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells

Acepodia closed its Series B round Tuesday morning, hoping to build upon CEO Sonny Hsiao’s work from when he was a biologist at UC Berkeley. The biotech plans to use the funds to advance its lead program through the end of a Phase I trial and launch a Phase II study, as well as to get two other candidates into the clinic.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}